Fulcrum Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for FULC, updated each market day.
FULC AI Sentiment
AI predicts Fulcrum Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Sector
Exchange
Market Cap
$287,640,658
Cap Tier
Employees
55
Headquarters
CAMBRIDGE, MA
Listed Since
July 18, 2019
Website
FULC Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
FULC Volatility
Fulcrum Therapeutics, Inc. Common Stock has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
